Back to Search
Start Over
Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience.
- Source :
- Cancer Medicine; Apr2019, Vol. 8 Issue 4, p1442-1446, 5p
- Publication Year :
- 2019
-
Abstract
- Hepatocellular carcinoma (HCC) is a challenging to treat malignancy with few available systemic therapies. Angiogenesis has been implicated in the pathogenesis of HCC and prior studies have suggested a role for anti‐VEGF therapy. Prior to FDA approval of second‐line therapy for advanced HCC, from 2008 until 2017, we initiated bevacizumab monotherapy (5‐10 mg/kg every 2‐3 weeks) in 12 patients with intolerance of or progression during sorafenib therapy. Bevacizumab therapy was well tolerated with only 1/12 patients experiencing a grade 3‐4 treatment‐related adverse event (transient ischemic attack) and only 2/12 patients discontinued the therapy due to adverse events. Median overall survival was 20.2 months (IQR, 7.0‐43.5), with a median time to radiologic progression of 10.4 months (IQR, 2.8‐16.1) and a disease control rate of 54%. Taken together, our experience provides rationale for further prospective investigation of bevacizumab for the treatment of advanced HCC. [ABSTRACT FROM AUTHOR]
- Subjects :
- HEPATOCELLULAR carcinoma
TRANSIENT ischemic attack
BEVACIZUMAB
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 8
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Cancer Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 136152260
- Full Text :
- https://doi.org/10.1002/cam4.2015